Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2017 call → NOWe need answer YES/NO. Need analyze transcript. Question: does management explain where company's business is going by narrating what counterparties are themselves doing and scaling? Need identify if substantial part forward account consists of reporting on growth/expansion/ramp/adoption/program build-out of specific customers/partners etc already supplied, such that company's coming volume consequence of those parties' trajectories. Transcript: Management discusses supply issues, production delays, recapture, sales force, new products. They mention "customers" generally, "surgeons" waiting to move business back, "existing customer demand", "new surgeon customers". But no specific counterparties named or described as scaling their own operations. They talk about "sales recapture from previously affected customers" and "surgeons may be waiting to move business back until full product offering". This is about customers returning, not counterparties' own expansion. They mention "Asia-Pacific region growth" but not specific counterparties. They mention "LDR Spine" integration, "Mobi-C" demand, but not counterparties scaling. They mention "Persona Partial Knee" launch, "X-PSI guides" commercial availability. No narration of identifiable counterparties' own trajectories. Management explains outlook through own actions: production, supply, sales force incentives, new products, recapture. No. Answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.